- Home
- CBZ vs NRIX Comparison
CBZ vs NRIX Comparison
Compare CBZ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBZ | NRIX |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBZ | NRIX |
|---|---|---|
| Price | $54.85 | $21.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $55.00 | $33.93 |
| AVG Volume (30 Days) | 882.7K | ★ 1.3M |
| Earning Date | 10-28-2026 | 10-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | N/A |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $922,003,000.00 | $76,987,000.00 |
| Revenue This Year | $2.36 | $799.42 |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $19.36 | ★ N/A |
| Revenue Growth | 7.79 | ★ 99.31 |
| 52 Week Low | $24.29 | $9.00 |
| 52 Week High | $56.41 | $28.23 |
Technical Indicators
Market Signals| Indicator | CBZ | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 69.95 | 31.70 |
| Support Level | $54.37 | $21.23 |
| Resistance Level | $54.89 | $24.98 |
| Average True Range (ATR) | 0.09 | 0.91 |
| MACD | -0.14 | -0.21 |
| Stochastic Oscillator | 68.97 | 14.97 |
Price Performance
Historical ComparisonAbout CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.